Surveillance Study for HCC by Combining Biomarkers With Imaging (ALDUS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is intended to be a prospective observational study at multiple sites, not a randomized controlled trial (RCT). The uses of the biomarkers has been approved by government regulations and adopted for surveillance programs in some countries, thus an RCT which compares patients followed by US alone with patients followed by both US and the biomarkers would raise an ethical conflict, especially in countries where the biomarkers have been routinely used.

For this study, enrolled patients will be followed by US and the biomarkers at regular intervals and classified after completing the study to evaluate the clinical effectiveness of the biomarkers. The comparisons of sensitivity, specificity, and other parameters with respect to tumor characteristics will be made among US alone, the biomarkers, and combined use of US and the biomarkers. Also economical effectiveness of using the biomarkers will be investigated in this study.

Requirement status is monitored every month.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver

NCT01361061

Liver Cirrhosis

COMPLETED

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

NCT05064553

Hepatocellular Carcinoma Hepatocellular Cancer Hepatitis B +2 more

ACTIVE_NOT_RECRUITING

A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers

NCT02272504

Cirrhosis Chronic Liver Diseases

COMPLETED

New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules

NCT07272083

Hepatocellular Carcinoma

NOT_YET_RECRUITING

Downstaging Prediction Model for HCC

NCT07058649

HCC - Hepatocellular Carcinoma

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Data are being stored in the electric data capture (EDC) server.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with compensated cirrhosis. No discrimination by underlying causes will done.
* Patients aged 18 years and older
* Patients agree to the informed consent

Exclusion Criteria

* Patients with liver cancer at the time of enrollment
* Patients who have experienced HCC or other malignant tumor with in five (5) years
* Women with pregnancies
* Patients who are likely to be transplanted within one (1) year
* Patients with ≥ 3 mg/dL of total bilirubin
* Patients with uncontrollable ascites
* Patients with ≥ Grade II of hepatic encephalopathy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No